Pronounced Regional Variation in Esketamine and Ketamine Prescribing to US Medicaid Patients
medRxiv Preprint Server April 23, 2022 Alexia G. Aguilar, Burke A. Beauregard, Christopher P. Conroy et al. 2 citations preprint
Ketamine and esketamine effectively treat treatment-resistant depression without the therapeutic delay typical of other antidepressants and do not increase suicidal thoughts or behaviors in adolescents and young adults. Esketamine received FDA approval in March 2019.